Kymera Therapeutics Overview
Kymera Therapeutics Target Price
See Kymera Therapeutics's analyst price targets ($130) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$117.39
Average Target Price
$130.92
11.5% upside
11.5% upside13 analysts in the last 4 months
High: $170 | Low: $97
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-31 | GuggenheimBrad Canino | $170 | 44.8% upside |  |
| 2026-08-06 | Morgan StanleyJudah Frommer | $135 | 15% upside | |
| 2026-08-06 | Barclays | $139 | 18.4% upside | |
| 2026-08-05 | OppenheimerJeff Jones | $125 | 6.5% upside | |
| 2026-07-30 | Deutsche BankDavid Hoang | $120 | 2.2% upside | |
| 2026-07-28 | Guggenheim | $135 | 15% upside | |
| 2026-07-16 | Mizuho SecuritiesJoseph Catanzaro | $140 | 19.3% upside | |
| 2026-07-13 | RBC CapitalBrian Abrahams | $115 |  2% downside | |
| 2026-06-29 | Truist FinancialSrikripa Devarakonda | $136 | 15.9% upside | |
| 2026-06-26 | Canaccord GenuityEdward Nash | $129 | 9.9% upside | |
| 2026-06-26 | B.Riley FinancialKalpit Patel | $155 | 32% upside | |
| 2026-06-08 | Loop Capital MarketsLeah Rush Cann | $97 | 17.4% downside | |
| 2026-05-06 | Canaccord GenuityEdward Nash | $106 | 9.7% downside | |
| 2026-04-30 | Morgan StanleyJudah Frommer | $119 | 1.4% upside | |
| 2026-02-26 | Morgan StanleyJudah Frommer | $123 | 4.8% upside | |
| 2026-02-26 | RBC CapitalBrian Abrahams | $108 | 8% downside | |
| 2026-01-27 | BarclaysEliana Merle | $133 | 13.3% upside | |
| 2025-12-16 | RBC Capital | $103 | 12.3% downside | |
| 2025-12-11 | StephensSudan Loganathan | $110 | 6.3% downside | |
| 2025-12-11 | Mizuho Securities | $120 | 2.2% upside | |
| 2025-12-09 | Jefferies | $122 | 3.9% upside | |
| 2025-12-09 | Truist FinancialSrikripa Devarakonda | $116 | 1.2% downside | |
| 2025-12-09 | H.C. WainwrightAndrew Fein | $134 | 14.1% upside | |
| 2025-12-09 | Oppenheimer | $120 | 2.2% upside | |
| 2025-12-09 | Morgan Stanley | $127 | 8.2% upside | |
| 2025-12-09 | Piper Sandler | $125 | 6.5% upside | |
| 2025-12-09 | Wells FargoDerek Archila | $116 | 1.2% downside | |
| 2025-12-09 | Barclays | $119 | 1.4% upside | |
| 2025-12-08 | Leerink Partners | $118 | 0.5% upside | |
| 2025-12-08 | BTIGJeet Mukherjee | $138 | 17.6% upside | |
| 2025-12-08 | Stifel NicolausAlex Thompson | $114 | 2.9% downside | |
| 2025-11-26 | Truist Financial | $80 | 31.9% downside | |
| 2025-11-26 | UBS | $90 | 23.3% downside | |
| 2025-11-05 | H.C. Wainwright | $84 | 28.4% downside | |
| 2025-11-05 | Barclays | $70 | 40.4% downside | |
| 2025-11-04 | Morgan Stanley | $73 | 37.8% downside | |
| 2025-11-04 | Jefferies | $73 | 37.8% downside | |
| 2025-11-04 | OppenheimerJeff Jones | $67 | 42.9% downside | |
| 2025-11-03 | GuggenheimBrad Canino | $90 | 23.3% downside | |
| 2025-10-22 | BTIGJeet Mukherjee | $75 | 36.1% downside | |
| 2025-10-01 | Oppenheimer | $63 | 46.3% downside | |
| 2025-09-30 | Truist Financial | $68 | 42.1% downside | |
| 2025-09-18 | H.C. Wainwright | $70 | 40.4% downside | |
| 2025-09-16 | Barclays | $60 | 48.9% downside | |
| 2025-09-16 | RBC CapitalBrian Abrahams | $70 | 40.4% downside | |
| 2025-06-27 | OppenheimerJeff Jones | $53 | 54.9% downside | |
| 2025-06-26 | BTIGJeet Mukherjee | $59 | 49.7% downside | |
| 2025-06-25 | JefferiesKelly Shi | $64 | 45.5% downside | |
| 2025-06-03 | GuggenheimMichael Schmidt | $60 | 48.9% downside | |
| 2025-02-28 | H.C. Wainwright | $54 | 54% downside | |